Trial Profile
Effects of Multiple Doses of Abemaciclib on the Pharmacokinetics of Cytochrome P450 (CYP) 1A2, CYP2C9, CYP2D6, and CYP3A Substrates (Caffeine, Warfarin, Dextromethorphan, and Midazolam) in Cancer Patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Oct 2022
Price :
$35
*
At a glance
- Drugs Abemaciclib (Primary) ; Caffeine; Dextromethorphan; Midazolam; Warfarin
- Indications Cancer
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 02 Feb 2021 Status changed from active, no longer recruiting to completed.
- 16 Oct 2020 Planned End Date changed from 6 Oct 2020 to 6 Apr 2021.
- 18 Aug 2020 Planned End Date changed from 5 Oct 2020 to 6 Oct 2020.